Based on supply information shared by manufacturers, Health Canada has deemed glucagon (Glucagon for injection, rDNA origin), to be a Tier 3 shortage on April 20, 2023.
There are two injectable glucagon products approved by Health Canada. Eli Lilly, who manufactures Glucagon Emergency Kit (Glucagon for injection, rDNA origin), announced a global discontinuation of the product with an anticipated date of July 17, 2023.
Another available glucagon product approved in Canada is GlucaGen® (glucagon, rDNA origin) and is manufactured by Novo Nordisk. Novo Nordisk is reporting a shortage of their GlucaGen® HypoKit® due to supply issues. They have supply on-hand for existing customers until Fall 2023. They have indicated they cannot meet any additional needs or demand. The shortage is anticipated to end December 31, 2023.
Nasal Glucagon (Baqsimi®) will remain available in Canada for those aged 4 years and older experiencing severe low blood sugar (hypoglycemia) and when oral carbohydrates are not possible due to impaired consciousness.
Diabetes Canada understands that for many living with diabetes, glucagon for injection is critical for the treatment of low blood sugar (hypoglycemia). People living with diabetes who use this product are urged to speak with their physician/health-care team.
For additional information on the discontinuation of Glucagon Emergency Kit (Glucagon for injection, rDNA origin) please contact Eli Lilly at their Customer Response Centre 1-888-545-5972 from 9 am – 5 pm Eastern Time, Monday through Friday.
For information on the supply shortage of GlucaGen® (glucagon, rDNA origin), please contact Novo Nordisk Canada’s main distributor, Paladin Labs: 1-866-340-1112 or paladincs@endo.com